Loncastuximab tesirine 150 µg/Kg
20211204
Phase 2 small_molecule active
Quick answer
Loncastuximab tesirine 150 µg/Kg for Marginal Zone Lymphoma is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Marginal Zone Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active